Encephalitis and other neurologic complications, including acute necrotizing
encephalopathy, are associated with human herpesvirus-6
infection.
Antiviral treatment against human herpesvirus-6
infection is indicated only for immunocompromised patients. We describe a 15-month-old immunocompetent child with severe human herpesvirus-6-induced
encephalitis. The primary
infection was characterized by human herpesvirus-6
DNA in cerebrospinal fluid and serum, the presence of serum human herpesvirus-6
immunoglobulin M antibodies, and a rise in serum human herpesvirus-6
immunoglobulin G antibodies. Magnetic resonance imaging demonstrated multiple, partly symmetric, necrotic lesions in the pons, medulla oblongata, thalamus, external capsules, and occipital subcortical and cortical areas. High-dose
ganciclovir (18 mg/kg/day) was used as
antiviral treatment, without side effects. A pharmacokinetic analysis of
ganciclovir was performed. The initial recovery from severe disease was good. At 3-year follow-up, neurologic sequelae included
epilepsy and
ataxia. This case suggests that treatment with
ganciclovir should be considered in human herpesvirus-6
central nervous system infections because the neurologic sequelae may otherwise be severe. Controlled, prospective, clinical trials are warranted, to analyze the pharmacokinetics of
ganciclovir in infants.